Abstract 785P
Background
GTN involves malignant entities, such as choriocarcinoma (GCC), epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. We aimed to develop machine-learning (ML)-based prognostic models for patients with GTN to improve treatment decisions and personalized medicine.
Methods
The SEER database provided the data used for this study’s analysis (2000–2019). Patients were excluded if they did not meet certain criteria, such as a histology-confirmed diagnosis, previous history of cancer or other concurrent malignancies, non-placental origins, or unknown data. Cox regression and ML algorithms were used to construct prognostic models for predicting the 5-year survival. Patient records were randomly divided into a training set (70%) and a validation set (30%). A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of ML models.
Results
This study included 725 patients, of whom 139 had ETT, 107 had PSTT, and 479 had GCC. The median age was 37 years, and the most common stage was distant metastasis (n=330). The average tumor size was 6.13 cm, and 75.9% of patients underwent chemotherapy, 57.9% underwent surgery, and 4.3% underwent radiotherapy. Multivariate Cox regression revealed that older age, marital status, metastasis, and radiotherapy were poor prognostic factors, whereas surgery was a good prognostic factor. ML models revealed that the most important factors that influenced the model prediction performance were tumor size, years of diagnosis, and race. The online calculator, which is based on ML models, allows for real-time personalized survival predictions, and can be accessed through the following link: https://sakhrshwayyat.shinyapps.io/Gestational_Trophoblastic_Neoplasia/.
Conclusions
Our study revealed the critical components of clinical decision-making. The designed models and online prediction resources can significantly facilitate personalized treatment planning and enhance the clinical outcomes of patients with GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
782P - Predicting survival in malignant struma ovarii (MSO): A machine learning approach
Presenter: Sakhr Alshwayyat
Session: Poster session 02
Resources:
Abstract
783P - ESCAT gene actionability detection in early-stage ovarian: A descriptive analysis of an Italian referral center
Presenter: Floriana Camarda
Session: Poster session 02
784P - Prognostic nomograms for gestational and non-gestational choriocarcinoma: A population-based study
Presenter: Mustafa Alshwayyat
Session: Poster session 02
786P - Exploring risk factors for recurrence in stage I uterine leiomyosarcomas: Is there a subgroup with a favorable prognosis?
Presenter: Alejandro Gallego
Session: Poster session 02
787P - First-in-human, phase I study of CBP-1008, a first-in-class bi-specific ligand drug conjugate (Bi-XDC), in patients with advanced solid tumors
Presenter: Ning Li
Session: Poster session 02
788P - Pembrolizumab plus lenvatinib (PL) in recurrent clear cell gynecological cancer (CCGC): Phase II LARA trial (GCGS-OV4/ APGOT-OV3)
Presenter: Natalie Ngoi
Session: Poster session 02
789P - Translational study and preliminary clinical trial of WX390 monotherapy in cancers with concurrence of PIK3CA and ARID1A mutations
Presenter: Jiajia Li
Session: Poster session 02
790P - The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs)
Presenter: Carmen Garcia Duran
Session: Poster session 02
791P - Activity of ERK1/2 inhibitor ASTX029 in patients with gynecological malignancies harboring genomic alterations in the MAPK pathway
Presenter: Geoffrey Shapiro
Session: Poster session 02
792P - The differences in immunogenicity of TP53 mutated endometrial-, high-grade serous ovarian- and triple negative breast carcinomas
Presenter: Alain Zeimet
Session: Poster session 02